Anthem Biosciences Limited Key Financial and Operational Indicators Verified for Multiple Fiscal Years
K.P. Rao & Co, Chartered Accountants, has conducted a verification of key financial and operational performance indicators (KPIs) for Anthem Biosciences Limited, based on financial statements and supporting documentation provided by the Company. The verification covered several periods, assessing metrics including total revenue, EBITDA, Profit After Tax (PAT), and various efficiency ratios.Key Financial Performance Indicators (KPIs)
The following table presents the verified financial metrics for Anthem Biosciences Limited across several fiscal periods.| Financial Metrics | Unit | Period 1 | Period 2 | Period 3 | Period 4 | Period 5 | Period 6 | Period 7 |
|---|---|---|---|---|---|---|---|---|
| Total Revenue from operations | ₹ million | 21,243.33 | 18,445.53 | 14,193.70 | 10,569.24 | 72,312.56 | 5,885.99 | 8,635.50 |
| Year-on-year (YoY) Revenue Growth | (%) | 15.17 | 29.96 | 34.29 | -14.16 | 11.60 | NA | 46.72 |
| Revenue from Contract Research, Developmental & Commercial Manufacturing (CRDMO) | ₹ million | 17,727.68 | 15,060.93 | 10,831.69 | 8,080.92 | 9,472.12 | 4,269.60 | 7,15.57 |
| Revenue from Specialty Ingredients (SI) | ₹ million | 3,515.65 | 3,384.60 | 3,362.01 | 2,488.32 | 2,840.44 | 1,616.29 | 1,629.93 |
| Ratio of revenue from operations from CRDMO: SI | Ratio | 83:17 | 82:18 | 76:24 | 76:24 | 77:23 | 73:27 | 81:19 |
| Material Margin (RMR) | ₹ million | 13,120.50 | 11,006.41 | 8,198.18 | 7,176.47 | 8,223.32 | 3,516.32 | ----- |
The table below details the company's profitability and capital efficiency metrics:
| Metric | Unit | Period 1 | Period 2 | Period 3 | Period 4 | Period 5 | Period 6 | Period 7 |
|---|---|---|---|---|---|---|---|---|
| EBITDA | ₹ million | 8,971.69 | 6,837.80 | 5,799.55 | 4,460.53 | 5,873.13 | 2,215.03 | 3,275.04 |
| YoY EBITDA Growth | (%) | 31.21 | 31.51 | 16.57 | -24.05 | NA | NA | 47.86 |
| EBITDA margin | (%) | 47.07 | 36.81 | 36.25 | 44.53 | 46.85 | 37.28 | 37.43 |
| PBT | ₹ million | 8,242.40 | 6,568.68 | 4,773.78 | 4,972.98 | 5,467.40 | 2,086.93 | 3,775.09 |
| Profit after tax (PAT) | ₹ million | 5,917.92 | 4,512.59 | 3,673.10 | 3,851.85 | 4,055.39 | 1,571.04 | 2,13.60 |
| YoY PAT Growth | (%) | 31.4 | 22.86 | -4.6 | -5.02 | NA | NA | 55.51 |
| PAT margin | (%) | 25.95 | 23.38 | 24.77 | 33.97 | 31.68 | 25.12 | 26.82 |
| Return-on-equity (ROE) | (%) | 21.71 | 20.82 | 20.04 | 24.89 | 39.44 | NA | 23.82* |
| Post-tax ROCE | (%) | 30.78 | 26.88 | 25.71 | 37.69 | 59.48 | NA | 29.59* |
| Net Cash (Net debt) | ₹ million | 13,743.54 | 6,243.69 | 4,109.03 | 7,106.54 | 5,825.45 | 6,466.59 | 5,447.14 |
| Net Cash (Net debt) / EBITDA | Ratio | 1.53 | 0.91 | 0.79 | 1.59 | 0.99 | -1.46 | 0.83 |
| Revenue/Employee | ₹ million | 9.31 | 8.95 | 7.78 | 6.52 | 8.05 | 6.60* | 8.80* |
Operational and Management Metrics
Operational data provides insights into the company's size and asset management.| Operational Metrics | Unit | Period 1 | Period 2 | Period 3 | Period 4 | Period 5 | Period 6 | Period 7 |
|---|---|---|---|---|---|---|---|---|
| Number of Employees | # | 2,282 | 2,062 | 7,825 | 11,621 | 8,530 | 2,784 | 1,963 |
| Number of Scientific Staff | # | 1,117 | 1,015 | 972 | 894 | 874 | 951 | 1,005 |
| Number of PhDs | # | 32 | 35 | 35 | 22 | 29 | 38 | 35 |
| Inventory Days | Days | 104.46 | 1135.26 | 103.21 | 98.07 | 37.69 | 209.45* | 773.79 |
| Net Working Capital Days | Days | 198.06 | 222.15 | 248.63 | 241.94 | 137.21 | NA | 236.44 |
Key Metric Definitions
Several specific metrics utilized in the report were defined as follows:- Revenue from CRDMO (Contract Research, Developmental & Commercial Manufacturing Operations): This revenue comprises income derived from the discovery stage and R&D studies for molecules in other stages, as well as the manufacturing of commercialized products and developmental batches.
- Revenue from SI (Specialty Ingredients): This represents revenue derived from the manufacturing of specialty ingredients.
- CRDMO: SI Ratio: This ratio expresses the revenue derived from CRDMO versus SI as a proportion out of a total of 100.
- Material Margin: This margin is determined by deducting the Cost of Goods Sold from the Revenue from Operation.
- EBITDA: EBITDA is calculated as the sum of profit/loss before tax, plus depreciation and amortization expense and finance costs less other non-operating income.
- EBITDA Margin: This is calculated by dividing EBITDA by revenue from operations along with other operating income, and it is noted as a Non-GAAP Measure.
- PAT Margin: This is calculated as PAT divided by total revenue, and it is noted as a Non-GAAP Measure.
- ROE (Return-on-equity): This is calculated as profit after tax divided by average net worth for the current and preceding Fiscal year, and it is noted as a Non-GAAP Measure.
- Post-tax ROCE: This metric is calculated as earnings before interest and taxes times (1 - tax rate), divided by average capital employed. Average capital employed is the sum of average net worth, average net debt, average lease liability and average deferred tax liability for the current and preceding Fiscal. It is a Non-GAAP Measure.
- Gross Fixed Asset Turnover: This is calculated as total revenue from operations divided by average gross fixed assets.
- Net Cash: Net Cash is calculated as the sum of cash and cash equivalents, bank balance, and investment in mutual funds less gross debt. It is a Non-GAAP Measure.
- Net Cash / EBITDA: This is calculated as Net Cash divided by EBITDA, and it is a Non-GAAP Measure.
- Revenue/Employee: This is calculated as revenue from operations for the fiscal year, divided by the number of employees as of the end of the fiscal year.
- Net Working Capital Days: Calculated as net working capital divided by revenue from operations multiplied by 365 for Financial Years.
- Inventory Days: Calculated as average inventory divided by cost of goods sold multiplied by 365 for Financial Years.
ANTHEM Stock Price Movement
Anthem Biosciences Limited shares on Tuesday slipped by 1.12% to settle at ₹787.35. The stock finished the day having traded 293,810 shares, marking a downward move in the market.Disclaimer: Due care and diligence have been taken in compiling and presenting news and market-related content. However, errors or omissions may arise despite such efforts.
The information provided is for general informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any securities. Readers are advised to rely on their own assessment and judgment and consult appropriate financial advisers, if required, before taking any investment-related decisions.
Any views, opinions, or statements expressed, where applicable, are those of the respective analysts or experts and do not reflect the views of this website. The website has no association with such viewpoints and does not assume any responsibility for them.
Last edited by a moderator: